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Abstract
Glioma growth and progression are characterized by abundant
development of blood vessels that are highly aberrant and poorly
functional, with detrimental consequences for drug delivery effi-
cacy. The mechanisms driving this vessel dysmorphia during tumor
progression are poorly understood. Using longitudinal intravital
imaging in a mouse glioma model, we identify that dynamic
sprouting and functional morphogenesis of a highly branched
vessel network characterize the initial tumor growth, dramatically
changing to vessel expansion, leakage, and loss of branching
complexity in the later stages. This vascular phenotype transition
was accompanied by recruitment of predominantly pro-inflamma-
tory M1-like macrophages in the early stages, followed by in situ
repolarization to M2-like macrophages, which produced VEGF-A
and relocate to perivascular areas. A similar enrichment and
perivascular accumulation of M2 versus M1 macrophages corre-
lated with vessel dilation and malignancy in human glioma
samples of different WHO malignancy grade. Targeting macro-
phages using anti-CSF1 treatment restored normal blood vessel
patterning and function. Combination treatment with chemother-
apy showed survival benefit, suggesting that targeting macro-
phages as the key driver of blood vessel dysmorphia in glioma
progression presents opportunities to improve efficacy of
chemotherapeutic agents. We propose that vessel dysfunction is
not simply a general feature of tumor vessel formation, but rather
an emergent property resulting from a dynamic and functional
reorganization of the tumor stroma and its angiogenic influences.
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Introduction
Angiogenesis, the formation of new blood vessels from preexisting
ones (Risau, 1997), establishes oxygen supply to growing tumors
and is initiated by hypoxia-induced expression of pro-angiogenic
factors, such as vascular endothelium growth factor (VEGF). In
contrast to developmental and physiological angiogenesis, tumor
angiogenesis generates a chaotic blood vessel network, featuring
tortuous, dilated, and non-hierarchically organized vessels (Bergers
& Benjamin, 2003; Baluk et al, 2005). Current concepts suggest that
this dysmorphia of tumor vessels causes irregular blood flow, vascu-
lar leakage, edema formation, and limits systemic delivery of
chemotherapeutics to the tumor (Carmeliet & Jain, 2011).
Tumor-associated macrophages are a major component of the
tumor stroma (Qian & Pollard, 2010; Noy & Pollard, 2014), and their
accumulation correlates with poor prognosis for patients (Zhang
et al, 2012). Among multiple roles in tumor progression, macro-
phages have been shown to modulate angiogenesis (Zumsteg &
Christofori, 2009; Qian & Pollard, 2010) and to limit the efficacy of
anti-tumoral therapies (De Palma & Lewis, 2013). In gliomas,
myeloid cell depletion using various approaches has led to contra-
dictory results: On one hand, genetic or local pharmacogenetic abla-
tion of macrophage populations slows down glioma progression,
suggesting a tumor supportive role, potentially through modulation
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of angiogenesis (De Palma et al, 2005; Zhai et al, 2011). On the
other hand, pharmacological depletion of macrophages using ganci-
clovir reportedly results in accelerated tumor growth with minor
effects on vessel density (Galarneau et al, 2007).
Current limitations in the resolution of non-invasive in vivo
imaging technologies do not allow a detailed follow-up of vascular
patterning in glioma in a time-dependent manner. The poor accessi-
bility of glioma tissue to intravital light microscopy in experimental
models, and the chaotic nature of tumor vessels provide substantial
challenges to our ability to resolve vascular patterning mechanisms
in glioma angiogenesis at the cellular level. Therefore, the questions
precisely when and where which macrophage populations influence
tumor vessel patterning, and how, require further investigation.
Here, we used a surgical cranial window model (Ricard et al,
2014) and high-resolution two-photon microscopy, to elucidate the
details of blood vessel morphogenesis during glioma progression
in vivo. We demonstrate that contrary to current concepts, initial
tumor blood vessel formation is highly functional, resulting in
homogenous caliber, branching blood vessels with barrier proper-
ties and effective perfusion. During tumor growth, blood vessel
patterning subsequently deteriorates with branching profoundly
reduced at the expense of increased vessel diameter associated with
recruitment and polarization of VEGF producing alternative acti-
vated M2-like macrophages that cluster tightly around blood
vessels. We propose that vessel abnormalization limiting
chemotherapeutic efficacy is driven by infiltrating and M2-polar-
izing macrophages, which redistribute VEGF bio-availability and
alter its gradient in the tumor microenvironment.
Results
Progressive blood vessel dysmorphia during glioma growth
In order to visualize changes in the vasculature during glioma
progression, we implemented a glioma mouse model adapted for
intravital imaging by multiphoton microscopy (Ricard et al, 2014).
In our adaptation of this model, spheroids of syngenic C57Bl6
mouse CT2A (Seyfried et al, 1992; Oh et al, 2014) and GL261
(Szatmari et al, 2006) glioma cells modified to stably express blue
fluorescent protein TagBFP (Subach et al, 2008) were engrafted in
the endothelial-specific Pdgfb-iCre line (Claxton et al, 2008) and in
Cdh5-iCre (Sorensen et al, 2009) crossed with the ROSAmT/mG
reporter mouse (Muzumdar et al, 2007). Tamoxifen-induced activa-
tion of membrane-targeted GFP (mG) in brain endothelial cells was
performed 10 days before tumor implantation, allowing us to follow
blood vessel growth over time. Other non-tumor and non-endothe-
lial cells derived from the host expressed membrane-targeted red
fluorescent protein tdTomato (mT), enabling to simultaneously
detect also pericytes, macrophages, and glial cells.
Hypoxia is one of the main triggers of tumor angiogenesis
(Maxwell et al, 1997; Stoeltzing et al, 2004; Jensen et al, 2006).
Indeed, regions in the glioma tumor core upregulated hypoxia
responsive genes including glut1 (Fig 1A) and hif1a (Fig EV1A).
Timelapse imaging identified active dynamic tip cell sprouting, con-
firming the highly angiogenic nature of the tumor environment
(Fig 1B, Movie EV1). However, over time we observed a progressive
deterioration of blood vessel patterning. Whereas early vessel
formation (2-week tumor growth) exhibited hallmarks of sprouting
angiogenesis, forming normal caliber vessels and regular branching
similar to the healthy contralateral hemisphere, vessels at late stages
(5 weeks) showed significantly reduced branching but profoundly
increased vessel diameter (average threefold) (Figs 1C and D, and
EV1C). This apparent loss of vessel size control and loss of branch-
ing complexity (Fig 1D and E) during progressive tumor growth
(Fig EV1D) was associated with altered perfusion of the blood
vessel network, identified by FITC-dextran perfusion (Fig 1F and
G). In addition, Evan’s blue extravasation illustrated blood vessel
leakiness at late-stage tumor growth (Fig 1H and I). Endothelial
specificity of Pdgfb-iCre recombination was confirmed by CD31 co-
staining (Fig EV1B) and showed a very high percentage of endothe-
lial cell recombination in this brain tumor model. Cre-expression
from the second endothelial cell-specific line Cdh5-iCre also
confirmed selectivity, but with lower recombination efficiency
(Fig EV1C).
Blood vessel dysmorphia coincides with macrophage recruitment
Studying the tumor microenvironment in search for factors that
could explain blood vessel changes at late-stage glioma growth, we
observed concomitant recruitment of host cells (mT positive)
located in close proximity to blood vessels in late-stage tumor
growth. Immunolabeling identified these cells as F4/80-positive
macrophages (Fig 2A). More selective markers for innate or adap-
tive immunity cell types confirmed a major recruitment of macro-
phages, but very few T cells, B cells, natural killer cells, neutrophils,
and dendritic cells (Appendix Fig S1A–F). To label and track
myeloid cells, we crossed the Csf1r-Mer-Cre-Mer mouse line (Qian
et al, 2011) with the ROSAmT/mG reporter mouse line (Muzumdar
et al, 2007), which, following tamoxifen injection, allows the visual-
ization of mG-positive myeloid cells. In vivo imaging during glioma
progression at early (2 weeks)- and late-stage growth (4 weeks)
confirmed the recruitment of Csf1r-Cre reporter (mG)- positive
macrophages concomitant with the observed blood vessel diameter
increase (Movies EV2 and EV3). Analysis of the contralateral hemi-
sphere revealed no GFP reporter-positive cells, indicating that the
inducible Csf1r-Mer-Cre-Mer promoter drives specific recombination
in recruited myeloid cells but not in brain resident macrophages and
microglia (Appendix Fig S2A).
Glioma-invading macrophages are bone marrow derived
Transplantation of LifeAct-GFP bone marrow (Riedl et al, 2010) into
irradiated ROSAmT/mG reporter mice followed by tumor implantation
revealed exclusively LifeAct-GFP-positive macrophages surrounding
blood vessels at late tumor growth, demonstrating bone marrow
rather than brain-derived local macrophage sources (Fig 2B). The
transplanted LifeAct-GFP-positive macrophages spread into the
tumor in early glioma growth but were later located close to blood
vessels with a threefold decrease of macrophage to blood vessel
distance from early- to late-stage tumor growth (Fig 2C). Moreover,
LifeAct-GFP-positive macrophages showed increased proliferation
during late-stage tumor growth as identified by an approximately
twofold increase in Ki67-positive macrophages compared to early
stage (Appendix Fig S3). To confirm that LifeAct-GFP was only
expressed in bone marrow-derived macrophages and not resident
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Figure 1. Blood vessel abnormalities arise during progressive glioma growth.
A Glucose transporter1 (Glut1) immunohistochemistry on sections of 5-week growth glioma in ROSAmT/mG::Pdgfb-iCre mouse (50-lm depth stack). Hypoxic tumor cells
upregulate Glut1.
B Still image of two-photon live imaging on 2-week growth glioma implanted in ROSAmT/mG::Pdgfb-iCre mouse demonstrating tip cell filopodia extension indicative of
sprouting. See Movie EV1.
C Representative images of two-photon live imaging of the same glioma area of the same mouse on 2- and 5-week growth glioma (BFP positive) implanted in
ROSAmT/mG::Pdgfb-iCre mouse (350-lm depth stack). Note differences in network complexity and vessel diameter.
D Blood vessel diameter quantification: sprouting blood vessels at 2-week growth present caliber comparable to vessels in the healthy brain (hb). At 5-week growth,
tortuous blood vessels in the tumor are significantly more dilated than in the healthy brain (n = 8 mice).
E Branchpoint quantification during glioma growth (n = 8 mice).
F Two-photon live imaging of vessel perfusion using FITC-dextran IV injection in ROSAmT/mG mice (asterisks correspond to unperfused vessel segment) (300-lm depth
stack).
G Quantification of unperfused vessel segments (asterisks in F) shows increase during glioma growth (n = 5 mice).
H Tumor-bearing brain overview images after Miles assay.
I Late-stage glioma growth vessels are leaky compared to early tumor growth (n = 5 mice per group).
Data information: Statistical analysis (D, E, G, I) one-way ANOVA followed by multiple comparisons Tukey’s test. Error bars: mean  SD. Scale bars: (A) 250 lm; (B)
50 lm; (C,F) 150 lm; (H) 0.5 cm.
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macrophages, we imaged the contralateral hemisphere where no
GFP-positive cells were detected (Appendix Fig S2B). To understand
the contribution of resident brain macrophages/microglia in our
glioma model, we performed Iba1 immunostaining (Appendix Fig
S4A) and noticed that Iba1-positive cells were preferentially local-
ized at the tumor margin and not, in contrast to the F4/80-positive
bone marrow-derived macrophages (Appendix Fig S4B) in the
tumor core (Appendix Fig S4C).
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Figure 2. Macrophages invading growing glioma are bone marrow derived.
A F4/80 immunohistochemistry on a section of 5-week growth glioma implanted in ROSAmT/mG::Pdgfb-iCre mouse (50-lm depth stack).
B Two-photon live imaging of LifeAct-GFP bone marrow transplantation in 5-week implanted glioma in ROSAmT/mG mice (100-lm depth stack).
C Two-photon live imaging of LifeAct-GFP bone marrow transplantation in 3- and 5-week implanted glioma in ROSAmT/mG. Macrophages relocate close to blood vessels
during glioma growth (50-lm depth stack; n = 4 mice).
Data information: Statistical analysis: (C) t-test. Error bars: mean  SD. Scale bars: (A) 150 lm; (B) upper panels: 70 lm; (B) lower panels: 280 lm; (C) 100 lm.
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Macrophages switch from M1 to M2 polarization during
glioma growth
The role of macrophages in tumor biology depends on their activa-
tion state (Casazza & Mazzone, 2014). Circulating monocytes can
either polarize as M1 cytotoxic macrophages promoting a Th1
immune response and as such have an anti-tumoral effect, or as M2
immunosuppressive macrophages that drive Th2 responses and
thus have a pro-tumoral and pro-angiogenic effect through secretion
of growth factors including VEGF (Schmid & Varner, 2010). The
true heterogeneity of macrophages is likely even greater, with
subcategories to the M1/M2 profile emerging (Auffray et al, 2009).
Recent studies suggest that macrophages in the tumor microenvi-
ronment may be plastic, and possibly switch phenotype from M1 to
M2 during tumor growth (Zaynagetdinov et al, 2011; Sica et al,
2012).
To analyze macrophage polarization in the glioma setting, we
performed immunofluorescence labeling on thick sections at dif-
ferent stages of tumor growth. In early stages of tumor growth
(2 weeks), 72% of the macrophages were MHCIIhigh MRC1neg M1
macrophages and very few MHCIIlow MRC1+ M2 macrophages were
detected (Fig 3A and B). The opposite was observed in late-stage
tumor growth (5 weeks) where 89% of the macrophages were M2
MHCIIlow MRC1+ macrophages (Fig 3A and B). The specificity of
immunolabeling using MHCII and MRC1 for M1 and M2 macro-
phages, respectively, was confirmed with double staining in which
no overlap was observed between both populations (Appendix Fig
S5). The polarization of macrophage populations was further
assessed by flow cytometry analysis using Movahedi et al settings
(Movahedi et al, 2010), confirming the overall switch of monocyte-
derived cells to a M2 phenotype (Figs 3C and EV2). Interestingly,
the number of MRC1-positive macrophages significantly correlates
with blood vessel diameter increase during glioma growth, suggest-
ing a direct effect of the switch in macrophage polarization on blood
vessel morphology (Fig 3D).
These data are compatible with either an in situ switch within
the tumor microenvironment from M1 to M2 macrophages or with a
de novo recruitment of distinct populations. To distinguish between
these possibilities, we injected fluorescently labeled anti-MHCII anti-
body systemically in 3-week glioma-bearing mice and sacrificed
these animals at 6 h or 24 h post-injection. At the 6-h time-point,
immunostaining on brain tumor sections revealed that macrophages
in the tumor labeled with MHCII antibody were negative for MRC1
(Fig 3C). In contrast, at the 24-h time-point, 75% of the MHCII
labeled macrophages in the tumor were also positive for MRC1
immunolabeling, indicating that in this 24-h time window, originally
M1 macrophages positive for MHCII switched in situ to a M2 pheno-
type, expressing the MRC1 marker (Fig 3E).
M2 macrophage polarity correlates with blood vessel dysmorphia
in human glioma
To investigate the relevance of our findings in human pathology, we
collected fresh glioma samples from 29 patients of WHO grade II to
grade IV (Table EV1). Human glioma progression is characterized
clinically by blood vessel alteration and leakiness (Appendix Fig
S6). Performing immunostaining for Glut1 as a brain endothelial cell
marker, we observed, as in the mouse model, a stage-related change
of blood vessel patterning with loss of network complexity and
vessel diameter increase in high-grade gliomas (Fig 4A). Moreover,
immunolabeling of total and M1/M2 macrophages revealed an
intriguing similarity in phenotype and localization of macrophages
between the stages of the mouse model and human glioma (Fig 4B–
D). The number of M2 MRC1-positive macrophages significantly
correlated with vessel diameter in accordance with the WHO glioma
grade classification. These results would be compatible with the
idea of a direct relationship between M2 macrophages accumulation
and vessel mispatterning (Fig 4E).
Macrophage depletion restores blood vessel caliber and function
In order to understand the potential of anti-macrophage therapy
concerning blood vessel function and glioma progression, we inhib-
ited macrophage recruitment in the tumor microenvironment using
anti-CSF1 monoclonal antibody treatment. Systemic administration
of anti-CSF1 antibody in mice has previously been shown to effec-
tively inhibit macrophage differentiation, proliferation and survival
(Evans et al, 1989; Hume & MacDonald, 2012). At late-stage growth
(4 weeks), Glut1 and CD31 immunostaining revealed a profound
“normalization” of blood vessel parameters in anti-CSF1 antibody-
treated glioma-bearing mice compared to isotype-matched control
antibody treatment (Fig 5A and B). A 50% decrease in the total
population of macrophages (Fig 5C) was accompanied by a signifi-
cantly reduced blood vessel caliber (Fig 5A), partially restored Glut1
endothelial expression, indicating improved barrier-function
(Fig 5B), and restored vessel perfusion (Fig 5E). Unexpectedly,
macrophage depletion and vessel normalization were associated
with a significant twofold increase in tumor growth (Fig 5D). This
could be either related to improved vessel function or directly to
modulation/compensation of the immune response. To investigate a
potential immune response compensation because of the absence of
macrophages, we assessed neutrophil and myeloid-derived suppres-
sor cells (MDSCs) populations in response to the treatment by
immune-labeling for Ly6G or CD11B/Ly6C/G, respectively. We
observed a tendency of neutrophil accumulation (Appendix Fig
S7A–C), but not MDSCs following anti-CSF1 treatment (Swierczak
et al, 2014; Appendix Fig S7B–D). To further investigate the effects
of macrophage accumulation on glioma vessel parameters, we
treated early-stage tumor-bearing mice (3 weeks) with recombinant-
CSF1 protein. Enhanced tumor macrophage recruitment (plus 53%)
in early-stage tumors (Fig 6A and B) accelerated vessel dysmorphia
and diameter increase (63%) compared to control carrier treatment
(Fig 6A and C). In addition, recombinant CSF1 treatment signifi-
cantly delayed glioma growth (52% size reduction) compared to
control and anti-CSF1 antibody treatment (Fig 6D).
M2 macrophage-derived VEGF drives vessel dysmorphia in
late-stage glioma
We next asked whether and how the phenotypic macrophage switch
could explain the vascular changes and dysmorphia. Given the
significant correlation between M2 MRC1-positive macrophages and
blood vessel dilation during glioma growth (Fig 3D), and the
pronounced M2 accumulation around blood vessels, we searched
for an M2-derived factor that might mediate the effects. We
performed qPCR analysis of tumor macrophages after specific
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isolation by magnetic-activated cell sorting of M1 or M2 macro-
phages using anti-MHCII or anti-MRC1-coated beads, respectively
(Fig 7A). MHCII-sorted cells expressed more CCR7, CCL19, CXCL10,
and IL12 than MRC1-sorted cells (Fig 7A). On the contrary, MRC1-
sorted cells expressed significantly more TGFb and VEGF-A,
together with the M2 markers mannose receptor and CD209
(Fig 7A) (Bulnes et al, 2012). Given the cytokine profile of M2
macrophages and their perivascular accumulation in late-stage
tumors, it is conceivable that presentation, localization, and bio-
availability of VEGF-A will change during the transition from early-
to late-stage tumors. Indeed, in situ hybridization (Fig EV3A) and
receptor-body staining using soluble VEGFR1 (sFlt1) as a probe
(Figs 7B and EV3B) identified production and presentation of a
larger amount of VEGF-A in the direct vicinity of endothelial cells
A
B
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Figure 3. Concomitant macrophage accumulation and in situ switch from M1 to M2 phenotype with blood vessel abnormalities during glioma growth.
A MHCII and MRC1 immunohistochemistry on a section of 3- to 5-week growth glioma implanted in ROSAmT/mG::Pdgfb-iCre mouse. M1 macrophages, preferentially
located in hypoxic area, are abundant at 3 weeks and their number decreases at 5 weeks. M2 macrophages, preferentially located around blood vessels, are present
at a low level at 3 weeks and their number increases at 5 weeks.
B Macrophage quantification during glioma growth (n = 5 mice per group).
C MHCII and MRC1 macrophage population FACs analysis in 2-, 3-, 4-, and 5-week glioma (subsets in gated CD11b+ cells; n = 3 mice per group).
D Correlation analysis of M2-like macrophages accumulation (MRC1 positive) with vessel dysmorphia over glioma growth (n = 12 mice).
E MRC1 immunohistochemistry on 3-week growth glioma in ROSAmTmG::Pdgfb-iCremouse following MHCII-FITC labeled IV injection at 6 or 24 h (5-lm depth stack). Note
the segregation of MRC1 and MHCII cell labeling at 6 h and the overlapping (examples pointed with arrow heads) of these two markers at 24 h (n = 5mice per group).
Data information: Statistical analysis: (B) one-way ANOVA followed by multiple comparisons Tukey’s test; (D) Spearman’s correlation test; (E) t-test. Error bars:
mean  SD. Scale bars: (A) 200 lm; (E) 50 lm.
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(Fig EV3C). Too much VEGF and a lack of gradient have been
shown to stall sprouting while driving proliferation (Ruhrberg
et al, 2002; Gerhardt et al, 2003). In addition, our recent work on
the function of the VEGF-Dll4/Notch-VEGFR2 feedback loop in
sprouting angiogenesis predicted that endothelial cells over-
stimulated with VEGF and lacking a VEGF-gradient become
synchronized (Bentley et al, 2008, 2009, 2014; Ubezio et al, 2016)
and try to sprout at the same time, extending filopodia in every
A
B C
D
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Figure 4. Blood vessel dysmorphia is associated with macrophage polarization in progressive grades of human glioma.
A Glut1 immunohistochemistry on human grade II and grade IV glioma samples (50-lm depth stack). Blood vessel diameter increases and network complexity
decreases with increasing grade.
B CD68, MHCII, and MRC1 immunohistochemistry on human grade II and grade IV glioma samples (50-lm depth stack).
C Macrophage polarization quantification. Low-grade glioma is characterized by high number of M1 polarized macrophages. High-grade glioma is characterized by
high number of M2 polarized macrophages.
D Correlation analysis of M2-like macrophages accumulation (MRC1 positive) with vessel dysmorphia depending on the tumor grade.
E Quantification of macrophage distance to the nearest blood vessel. Macrophages relocate close to blood vessels in late-stage gliomas. For number of patients per
group, refer to Table EV1.
Data information: Statistical analysis: (A, C, D) one-way ANOVA followed by multiple comparisons Tukey’s test; (E) Spearman’s correlation test. Error bars: mean  SD.
n = 5 WHO grade II patients, n = 5 WHO grade III patients and n = 19 grade IV patients. Please refer to Table EV1. Scale bars: (A, B) 100 lm.
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direction leading to vessel diameter expansion. Live imaging
showed iterative bursts of lateral filopodia emanating from the
enlarged vessels, but failing to produce productive sprouts (Movie
EV4). Moreover, VEGF-A is also a potent vascular permeability
factor. The presentation of VEGF-A by M2 macrophages in close
contact with endothelial cells will thus likely cause or contribute
to the vascular leakage and perfusion defects observed in late-stage
gliomas (Fig 1H and I). As a consequence, sequestration of blood
vessels by macrophages is a likely mechanistic cause for the
observed hypoxic area expansion during glioma progression as
highlighted by Glut1 immunostaining (Appendix Fig S8).
Macrophage-derived VEGF depletion restores blood vessel caliber
and function
To study the contribution of M2 macrophages derived VEGF in
vascular dysmorphia, we analyzed the Vegfafl/fl::LysMCre mice
(Fig 7C–G) (Stockmann et al, 2008). Depletion of VEGF expression
in 61% of the myeloid cells invading the tumor revealed by soluble
Flt1 binding (Fig 7E) did not alter the total number of F4/80-positive
macrophages (Fig 7D). However, blood vessel caliber was
decreased by 53%, demonstrating the involvement of macrophage-
derived VEGF in blood vessel alteration (Fig 7A and F). Remark-
ably, the myeloid cell VEGF depletion was accompanied by a signifi-
cant 25% increase in tumor growth (Fig 7G), suggesting that the
macrophage-induced vessel dysmorphia driven by VEGF limits rapid
tumor expansion.
Moreover, administration of a soluble VEGF trap using sFlt1
also normalized the glioma vasculature (Fig EV4A) and altered
macrophage recruitment in the tumor microenvironment, poten-
tially by interfering with the VEGFR1/VEGF pathway in macro-
phages (Fig EV4B and C). Interestingly, however, this did not affect
tumor growth, showing that complete VEGF downregulation in the
tumor does not have the same effect as the specific depletion of
VEGF from perivascular M2 macrophages (Fig EV4D).
In order to analyze the specificity of vessel dilation for glioma
and its link to myeloid cell recruitment in the tumor microenviron-
ment, we inoculated B16 melanoma in the flank of wild-type mice
and depleted macrophages using anti-CSF1 mAb treatment
(Appendix Fig S9). As observed during glioma growth, melanoma
irrigating blood vessels significantly expanded over time during
tumor growth (Appendix Fig S9A and B). This vessel dilation corre-
lated with an accumulation of M2 macrophages in late-stage tumor
growth (Appendix Fig S9D). Depletion of macrophages nevertheless
induced a reduction of vessel caliber (Appendix Fig S9A–C), yet
with only minor effects on tumor volume (Appendix Fig S9C).
A
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Figure 5. Inhibition of macrophage recruitment restores patterning and
functionality of the blood vessel network in glioma.
A Glut1 immunohistochemistry on sections of 4-week growth glioma in
ROSAmT/mG mice treated with anti-CSF1 or control antibodies. Anti-CSF1
antibody treatment induces a twofold decrease in vessel caliber compared
to control antibody (n = 6 mice per group) (50-lm depth stack).
B Glut1 and MRC1 immunohistochemistry on 4-week growth glioma in
ROSAmT/mG mice treated with anti-CSF1 or control antibodies. Anti-CSF1
antibody induces a decrease in macrophage recruitment in the tumor
microenvironment associated with an improved blood brain barrier
functionality assessed by a better Glut1 blood vessel coverage compared to
control antibody-treated mice (50-lm depth stack).
C Macrophage quantification in response to anti-CSF1 or control antibody
treatment (n = 6 mice per group).
D Tumor volume quantification in response to anti-CSF1 or control
antibodies (n = 6 mice per group).
E Two-photon live imaging of vessel perfusion in 4-week implanted glioma
growth using FITC-dextran IV injection in ROSAmT/mG mice treated with
anti-CSF1 or control antibodies (asterisks correspond to unperfused vessel
segments).
F Quantification of unperfused vessel segments. Anti-CSF1 antibody
treatment induces a reduction in the number of unperfused vessel
segments (asterisks in E). (n = 5 mice per group) (300-lm depth stack).
Data information: Statistical analysis: (A, F) t-test; (C) one-way ANOVA followed
by multiple comparisons Tukey’s test; (D) Mann–Whitney U-test. Error bars: (A,
C, F) mean  SD; (D) median interquartile. Scale bars: (A, B, E) 150 lm.
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Macrophage depletion enhances chemotherapeutic
agent efficacy
To investigate the relevance of our findings in a therapeutic
treatment-based approach, we performed survival experiments
combining temozolomide (TMZ) recommended chemotherapeutic
agent for glioma treatment (Furnari et al, 2007; Sathornsumetee
et al, 2007) and anti-CSF1 monoclonal antibody treatment (Fig 8A).
For these endpoint survival studies, we adopted the classical cell
suspension injection model of glioma we previously used (Van
Woensel et al, 2017). Anti-CSF1 monoclonal antibody treatment
alone did not significantly affect animal survival compared to the
control group (Fig 8B). As previously shown in these glioma mouse
models, temozolomide treatment significantly improved median
survival compared to control mice (Fig 8B; Plowman et al, 1994;
Friedman et al, 1995) without side effects on the immune cell
compartment in the bone marrow (Fig EV5E). Interestingly, anti-
CSF1 monoclonal antibody treatment combined with temozolomide
treatment significantly potentiated the chemotherapeutic agent effi-
cacy with a further increase in the median survival compared to
mice treated with chemotherapeutic agent alone (Fig 8B). In order
to understand the cause of combination therapy survival benefit, we
performed immunostaining against activated caspase3 (Fig 8C–E)
and phospho-H2AX (Fig EV5A and B) used as a tumor DNA damage
marker. We observed a significant threefold increase in tumor cell
death in the anti-CSF1 and chemotherapy combined treatment
compared to chemotherapeutic treatment alone. Moreover, glioma
cell death was homogenous in the entire tumor when mice were
treated with the combination therapy compared to a patchy glioma
cell death pattern in the chemotherapy treatment alone suggesting
that improved vessel patterning (Fig 8D) and function allows a
better overall tumor targeting. In line with this idea of vascular
network functionality improvement, tumor hypoxia highlighted by
Glut1-positive tumor cells area was reduced in response to TMZ and
this effect was exacerbated following TMZ plus anti-CSF1 co-treat-
ment (Fig EV5C and D).
Discussion
Vascular endothelium growth factor derived from tumor-associated
macrophages has been shown to drive the formation of a high-
density vessel network in other mouse solid tumor models such as
breast cancer (Stockmann et al, 2008). Also, bone marrow-derived
cells (BMDCs) have been reported to invade glioma in response to
hypoxia and stimulate neovascularization (De Palma et al, 2007; Du
et al, 2008; Kioi et al, 2010). However, these fixed time-point and
mostly late-stage studies implied that tumor vessels already form as
tortuous and leaky conduits.
Our observations, using an in vivo longitudinal imaging
approach, instead argue that vascular network dysmorphia is
progressive and connected to changing stromal cell populations aris-
ing during late-stage growth. Interestingly, the combined vessel
A
B
C D
Figure 6. Promoting macrophage recruitment in glioma drives early
dysmorphia of the tumor blood vessel network.
A MRC1 immunohistochemistry on sections of 3-week growth glioma in
ROSAmT/mG mice treated with recombinant CSF1 or carrier. Recombinant
CSF1 treatment induces blood vessel enlargement in early tumors (50-lm
depth stack).
B Quantification of Tomato-positive macrophages. Recombinant CSF1
treatment induces increased macrophage recruitment compared to control
(n = 6 mice per group).
C Vessel diameter quantification. Recombinant CSF1 treatment drives blood
vessel diameter increase compared to control (n = 6 mice per group).
D Tumor volume quantification in 3-week glioma implanted mice treated
with recombinant CSF1, anti-CSF1 antibody, or control antibody.
Recombinant CSF1 treatment reduces tumor growth compared to control
(n = 6 mice per group).
Data information: Statistical analysis: (B, D) one-way ANOVA followed by
multiple comparisons Tukey’s test; (C) t-test. Error bars: (B, C) mean  SD; (D)
median interquartile. Scale bar: (A) 100 lm.
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patterning and tumor growth data suggest that vessel dysmorphia
can be disconnected from the actual size or growth of the tumor cell
population. Moreover, the distinct transition in vessel patterning
occurring between early- and late-stage glioma growth in the mouse
model, similarly characterized human samples of different WHO
malignancy grades. Our sequential in situ labeling of MHCII
followed by post-fixation MRC1 labeling indicates that this
progressive stroma alteration comprises a repolarization of M1-like
to M2-like macrophages within the tumor. Moreover, this in situ
repolarization to M2-like macrophages is accompanied by a
A
C D E
F G
B
Figure 7. Macrophage-derived VEGF depletion restores blood vessel architecture in glioma.
A qPCR analysis of CCR7, IL12, CCL19, CXCL10, MRC1, TGFb, CD209, and VEGF on RNA samples from MHCII or MRC1 tumor extracted macrophages (n = 5 isolation per group).
B sFlt1 binding assay on 5-week growth glioma section implanted in ROSAmT/mG::Pdgfb-iCre mouse. At late-stage tumor growth, M2 macrophages surrounding blood
vessels present very high amount of VEGF (binding sFlt1) to the neighboring endothelial cells (5-lm depth stack).
C F4/80 immunohistochemistry and sFlt1 binding on sections of 4-week growth glioma in Vegfafl/fl::LysMCre+ or Vegfafl/fl ::LysMCre mice (50-lm depth stack).
D Quantification of F4/80-positive macrophages. VEGF depletionin myeloid cells does not alter macrophages recruitment (n = 7 mice per group).
E Quantification of F4/80-positive macrophages binding sFlt1. VEGF depletion is effective in 61% of the macrophages invading the tumor (n = 7 mice per group).
F Vessel diameter quantification. Myeloid cell-derived VEGF depletion induces blood vessel “normalization” compared to control (n = 7 mice per group).
G Tumor volume quantification in 4-week growth glioma in Vegfafl/fl::LysMCre+ or Vegfafl/fl::LysMCre mice (n = 7 mice per group).
Data information: Statistical analysis: (D–F) t-test; (A, G) Mann–Whitney U-test. Error bars: (A, D–F) mean  SD; (G) median interquartile. Scale bars: (A, C) 100 lm.
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AB
C
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Figure 8. Combining macrophage depletion with chemotherapy increases survival of glioma-bearing mice.
A Experimental design for the survival trial: 8-week-old wild-type mice were injected with GL261 cells to induce glioma formation and were assigned randomly to
vehicle (n = 6), anti-CSF1 monoclonal antibody treatment (0.5 mg; n = 6), temozolomide treatment (40 mg/kg; n = 6), or temozolomide and anti-CSF1 mAb
combination treatment (n = 6). Mice were weighed once daily until they developed symptoms or reached the trial endpoint.
B Survival curves of the mice described in (A). Combination therapy is significantly more efficient than chemotherapy alone. (n = 6 mice per group).
C phospho-H2AX and Glut1 immunohistochemistry on 3-week growth glioma in wild-type mice treated as described in (A).
D, E Anti-CSF1 antibody in combination with temozolomide chemotherapeutic agent induces a wider tumor cell death efficiency with a significant decrease of blood
vessel caliber (D) and an increase in caspase3-positive tumor cells (E) (50-lm depth stack) (n = 6 mice per group).
Data information: Statistical analysis: (B) Multiple comparisons Mantel–Cox log-rank; (D, E) one-way ANOVA followed by multiple comparisons Tukey’s test. Error bars:
mean  SD. Scale bar: (C) 300 lm.
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profound spatial rearrangement of these cells, relocating close to
vessels to form perivascular clusters. Immunolabeling on sections
and qPCR on isolated macrophage populations illustrated strong
VEGF-A expression by M2 macrophages. Mechanistically, the relo-
cation of M2 macrophages and their VEGF production to the imme-
diate proximity of blood vessels could be the cause for reduced
branching at the expense of increasing vessel diameter in late-stage
tumors. Our previous studies identified elevated VEGF and
disrupted gradients to synchronize neighboring endothelial cells
through the VEGF-Dll4/Notch-VEGFR2 feedback loop (Ubezio et al,
2016). Such synchronization would be predicted to interfere with
branching vessel morphogenesis by disrupting differential endothe-
lial adhesion downstream of Notch (Bentley et al, 2014; Dejana &
Lampugnani, 2014). Administration of a monoclonal antibody
macrophage inhibitor targeting CSF1 maintains a functional and
highly branched vasculature until the late-stage glioma. This
suggests that the phenotypic switch of macrophages to the alterna-
tive activated M2 state contributes to the development of blood
vessel dysmorphia during glioma growth. However, the mecha-
nisms and outcomes of strategies targeting CSF1 or CSF1R are a
matter of ongoing debate. Indeed, a number of recent studies report
that macrophages stimulate tumor angiogenesis in a large variety of
models and their depletion is accompanied with reduced angiogene-
sis, attenuated tumor growth, and an improved response to chemo
and radiotherapies (DeNardo et al, 2011; Mitchem et al, 2013; Xu
et al, 2013; Hughes et al, 2015; Shiao et al, 2015). In gliomas,
myeloid cell depletion (De Palma et al, 2005; Zhai et al, 2011) or
CSF-1R inhibition (Pyonteck et al, 2013) has been shown to exert
anti-tumor effects or accelerated tumor growth (Galarneau et al,
2007; Stockmann et al, 2008).
In most studies, anti-CSF1R antibody-based therapies were
shown to decrease total macrophages population in various tumor
models in mice and patients (Manthey et al, 2009; Patel & Player,
2009; Ries et al, 2014; Cotechini et al, 2015). Other reports however
suggest that anti-CSF1R inhibitor appeared to re-educate macro-
phages rather than decreasing their numbers in mouse glioma,
correlating with tumor size reduction (Pyonteck et al, 2013). In our
experiments, targeting the CSF1R ligand CSF1 reduces the total
number of bone marrow-derived macrophages (Evans et al, 1989;
Hume & MacDonald, 2012). Importantly, effects from targeting
CSF1, unlike those achieved when targeting the receptor, should not
be confounded by potential activities of the second receptor ligand
IL-34 (De et al, 2016). Therefore, the use of CSF1R and CSF1 inhibi-
tors in glioma might have differential effects, as the downstream
signaling events triggered by CSF1 and IL-34 are distinct (Chihara
et al, 2010; Barve et al, 2013).
In our hands, targeting macrophage recruitment in the glioma
microenvironment with anti-CSF1 treatment or decreasing macro-
phage VEGF production similarly accelerate tumor growth, but
restore a functional and perfused blood vessel network that can
support effective delivery of anti-tumoral drugs. Indeed, macro-
phage depletion treatment in combination with recommended
chemotherapy significantly improved survival of glioma-bearing
mice and significantly increased glioma cell death homogeneously
within the tumor. Together with the improved structure and
perfusion of vessels after macrophage depletion, these data suggest
that the survival benefit of combination with chemotherapy is due
to an improved delivery of temozolomide. However, in the absence
of direct measurements of drug within the tissue, we cannot exclude
alternative effects including altered pharmacodynamics in
combination treatment. Importantly, although the pathogenesis of
the tumor and its mutational landscape will arguably differ in the
transplantable mouse tumor model compared to the in situ
tumorigenesis and progression in human tumors, the actual
phenotypic progression of the vascular network and the immune
cell recruitment appear highly similar, providing important new
insights into the longitudinal development of tumor vessel density
and functionality.
Materials and Methods
Animal procedure and glioma implantation
C57bl6 ROSAmTmG::Pdgfb-iCre mice or C57bl6 ROSAmT/mG::Cdh5-
iCre (8–12 weeks) were intraperitoneally injected once or three
times, respectively, with 80 lg/g of tamoxifen 10 days prior to
surgery. Craniotomy was realized by drilling a 5-mm circle in
between lambdoid, sagittal, and coronal sutures of the skull on
ketamine/xylazine anesthetized mice. A 250-lm diameter CT-2A
or GL261 glioblastoma cells spheroid was injected in the cortex
and sealed with a glass coverslip cemented on top of the mouse
skull.
Early-stage glioma growth was defined as ≤3 weeks.
Late-stage glioma growth was defined as ≥4 weeks.
For anti-CSF1 5A1 monoclonal antibody (BioXCell) treatment,
1-week growth glioma-bearing mice were injected IP with 0.5 mg/
week.
For rCSF1 (R&D Systems) protein treatment, 1-week growth
glioma-bearing mice were injected IP with 2 lg of protein every
other day.
For mouse recombinant sFlt1 (R&D Systems) protein treatment,
1-week growth glioma-bearing mice were injected IP with 2 lg of
protein every other day.
Humane endpoint of the experiment was reached when the
animal lost 15–20% of its original weight. The anesthetized mouse
was then transcardially perfused with 2% PFA solution. The mouse
brain was harvested and fixed overnight in 4% PFA at 4°C. For
in situ hybridization, the brain was post-fixed in 20°C cold
methanol. For immunocytochemistry, the brain was washed with
PBS and sectioned at the vibratome (200-lm thickness sections).
Tumor volume was measured on serial 200-lm tumor sections of
the whole tumor (obtained at the vibratome) under stereo-micro-
scope using Leica software according to Cavalieri’s principle.
The same implantation method was applied to C57Bl6
ROSAmTmG::Csf1r-Mer-iCre-Mer mice with intraperitoneal injection
of 80 lg/g of tamoxifen weekly over the course of the tumor
progression.
The same implantation method was applied to Vegf lox/lox
LysMCre mice. For our study, seven Vegfafl/fl::LysMCre+ female
mice (8–12 weeks) were compared to seven Vegfafl/fl::LysMCre
littermate female mice that were considered as control.
Both CT2A and GL261 cell lines were used for blood vessel and
macrophages characterization experiments. CT-2A cell line was
used for anti-CSF1, bone marrow transplant, and Vegf lox/lox
LysMCre mice experiments.
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Housing and all experimental animal procedures were performed
in accordance with Belgian law on animal care and were approved
by the Institutional Animal Care and Research Advisory Committee
of the KU Leuven (P105/2012).
Live imaging
For multiphoton excitation of endogenous fluorophores in experi-
mental gliomas, we used a Leica SP8 in vivo imaging system
equipped with a Chameleon Vision II titanium:sapphire laser
(Coherent Inc.) and integrated with devices for intravital imaging on
mice (stereotactic frame and body temperature monitoring/control).
Acquisition of ROSAmT/mG reporter mouse was performed at
950-nm fixed wavelength. BFP signal from genetically modified
tumor cells was acquired at 850-nm wavelength.
Immunofluorescence staining
200-lm brain vibratome sections were blocked and permeabilized
in TNBT (0.1 M Tris pH 7.4; NaCl 150 mM; 0.5% blocking reagent
from Perkin Elmer, 0.5% Triton X-100) for 4 h at room temperature.
Tissues were incubated with primary antibodies anti-Glut1 (Milli-
pore, 1:200), anti-Glut1 (Abcam, 1:200), anti-F4/80 (Life Technolo-
gies, 1:100), anti-MHCII (Thermo Scientific, 1:100), anti-MRC1
(R&D Systems, 2 lg/ml), anti-MRC1 (Bio-Rad, 1:100), anti-CD68
(Bio-Rad, 1:100), anti-Hif1a (Thermo Scientific, 1:100), anti-CD31
(Abcam, 1:100), anti-CD3 (Abcam, 1:100), anti-CD19 (Cell Signaling
Technology, 1:100), anti-CD11c (AbD Serotec, 1:100), anti-NK1-1
(Biolegend, 1:100), LY6G (Biolegend, 1:100), anti-Ki67 (Abcam,
1:100), anti-active Caspase3 (Abcam, 1:200), or anti-phospho-
H2AX-S139 (Cell Signaling Technology, 1:100) diluted in TNB Triton
buffer overnight at 4°C, washed in TNT buffer (0.1 M Tris pH 7.4;
NaCl 150 mM, 0.5% Triton X-100) and incubated with appropriate
secondary antibody (coupled with Alexa 488/555/647, Life Tech-
nologies, 1:200) diluted in TNB Triton buffer overnight at 4°C.
Tissues were washed and mounted on slides in fluorescent mount-
ing medium (Dako). Images were acquired using a Leica TCS SP8
confocal microscope.
For human samples, fresh tissues were rinsed in PBS and fixed
overnight in 4% PFA at 4°C. Samples were washed in PBS and
sectioned (200 lm) at the vibratome. Sections were subjected to a
first step of permeabilization in 20°C cold methanol for 1 h at
20°C. Samples were washed in PBS, and the standard staining
protocol was then applied starting with blocking and permeabiliza-
tion in TNBT buffer.
In situ hybridization
Probes for ISH were made by PCR amplification and verified by
sequencing. PCR products were cloned into Zero Blunt TOPO (Life
Technologies) according to the instructions of the manufacturer.
In situ hybridization was realized on 5-week growth mouse
glioma sample 4% PFA fixed 15-lm cryosections. Sections were
dried and fixed in PFA 4% for 20 min at room temperature. After
washes, the samples were treated with 5 lg/ml proteinase K/PBST
for 11 min and post-fixed for 15 min in 4% PFA. After washing in
PBST, samples were incubated with hybridization mix (50% forma-
mide, 1.3× SSC, 5 mM EDTA, 50 mg/ml yeast RNA, 0.2% Tween-
20, 100 mg/ml heparin, 10% CHAPS) for 1 h at 70°C and then
overnight in hybridization mix containing the probe at 70°C. The
following day, samples were extensively washed with hybridization
mix and MABT (100 mM maleic acid, 150 mM NaCl, 1% Tween-
20, pH 7.5) before being blocked for 2 h in MABT/2% blocking
reagent (Boehringer Mannheim)/20% goat serum. The samples
were then incubated overnight at room temperature with blocking
buffer containing anti-DIG-AP antibody (Roche). Next, the samples
were washed in MABT for 48 h, rinsed in fresh NTMT (100 mM
NaCl, 100 mM Tris–HCl pH 9.5, 50 mM MgCl2, 10% Tween-20),
and developed with NTMT/0.33 mg/ml nitroblue tetrazolium
(NBT), 0.05 mg/ml 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) at
37°C.
Soluble Flt-1 binding assay
Freshly sectioned 200-lm brain slices were blocked and permeabi-
lized in TNBT (0.1 M Tris pH 7.4; NaCl 150 mM; 0.5% blocking
reagent from Perkin Elmer, 0.5% Triton X-100) for 2 h at room
temperature. Tissues were incubated with 1 lg/ml recombinant
mouse soluble Flt-1 FC chimera (R&D Systems) diluted in TNB
Triton buffer for 2 h at room temperature. Samples were rinsed
three times in TNT buffer and subjected to 4% PFA fixation for
2 min. Samples were washed in TNT buffer and incubated in Alex-
a647 coupled anti-human IgG secondary antibodies (Life Technolo-
gies, 1:200) diluted in TNB Triton buffer overnight at 4°C. Tissues
were washed and mounted on slides in fluorescent mounting
medium (Dako). Images were acquired using a Leica TCS SP8 confo-
cal microscope.
Glioma cell culture
CT-2A and GL261 glioma cells were cultured in DMEM (Life Tech-
nologies) supplemented with 10% FBS (Life Technologies), 1%
penicillin/streptomycin (Life Technologies), and 1% glutamine (Life
Technologies) until a maximum of 10 passages. Spheroids were
obtained by seeding the glioma cells for 48 h on non-adherent
culture dishes. Spheroids of 200–250 lm were selected for
implantation.
Vessel perfusion assay
Glioma-bearing mice from 2- to 5-week growth were anesthetized
and injected intravenously with 100 ll of FITC labeled
2,000,000 MW dextran (Life Technologies). Blood vessel perfusion
was visualized in vivo using our live imaging settings.
Vessel permeability assay
For Miles assay, glioma-bearing mice from 2- to 5-week growth
were anesthetized and injected intravenously with 100 ll 1%
Evan’s blue solution (Sigma). Thirty minutes after injection, mice
are sacrificed and transcardially perfused with 2% PFA solution.
Dissected tumors were weighed and incubated in formamide solu-
tion at 56°C for 24 h to extract the dye. The absorbance of the solu-
tion was measured with a spectrophotometer at 620–405 nm. Three
mice per week were analyzed. Data are expressed as fold increase
compared to 2-week glioma growth with weight normalization.
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Bone marrow transplantation
Recipient 10-week-old mice were lethally irradiated (9.5 Gy) and
then intravenously injected with 107 bone marrow cells from
LifeAct-GFP mice 16 h later. Tumor implantation experiments were
initiated 5 weeks after bone marrow reconstitution. Blood cell count
was determined using a hemocytometer on peripheral blood
collected by retro-orbital bleeding.
Flow-cytometric staining of tumor-infiltrating myeloid cells
Tumor-bearing mice were anaesthetized by IP injection of 100 ll
sodium pentobarbital. Both femoral arteries were opened, and the
animals were perfused through the left cardiac ventricle with 50 ml
cold PBS. Tumors were harvested and incubated with RPMI medium
containing 10% FCS, 2.5 mg/ml collagenase D, and 5 U/ml DNase I
for 30 min at 37°C. After incubation, the digested tissue was passed
through a cell strainer and thoroughly washed. Cells were stained
with the following monoclonal antibodies: anti-CD45 Alexa Fluor
700 (eBioscience), anti-CD11b BV421 (BD), anti-Ly6C Alexa Fluor
647 (AbD Serotec), anti-Ly6G FITC (BD), anti-MHCII PerCP-Cy5.5
(Biolegend), and anti-MRC1 PE (Biolegend). For the MRC1 staining,
cells were fixed and permeabilized by using the LEUCOPERMTM
reagents (AbD Serotec). As a control, cells were stained with the
appropriate isotype control. To exclude dead cells, cells were
stained with the Zombie YellowTM dye (Biolegend). Data acquisition
was performed on the BD LSRFortessa and analysis was performed
with FlowJo_V10.
MHCII-positive cell tracking
ROSAmTmG glioma-bearing mice of 3-week growth were anes-
thetized and injected intravenously with 200 ll of FITC labeled
anti-MHCII HLA-DR (BD Biosciences). After 6 or 24 h of antibody
circulation, mice were sacrificed and transcardially perfused with
2% PFA solution. Harvested brains were then subjected to immuno-
labeling.
Macrophages extraction and qPCR analysis
Three-week growth CT-2A gliomas were harvested from six wild-
type bearing mice, minced with a scalpel, and incubated in 5 ml
Dulbecco’s modified Eagle’s medium containing 2 mg/ml collage-
nase I (Invitrogen) for 45 min at 37°C with shaking every 15 min
followed by filtering through a 40-lm nylon mesh (BD Falcon). The
cells were then centrifuged at 1,000 g for 5 min at 4°C, resuspended
in buffer 1 (0.1% bovine serum albumin, 2 mM EDTA, pH 7.4, in
PBS), separated equally into two tubes, and incubated with either
anti-rat immunoglobulin G-coated magnetic beads (Invitrogen)
precoupled with rat anti-mouse MHCII antibody (Thermo Scientific,
1 lg) or rat anti-mouse MRC1 antibody (Bio-Rad; 1 lg) for 30 min
at 4°C in an over-head shaker. Beads were separated from the
solution with a magnetic particle concentrator (Dynal MPC-S, Invit-
rogen). The beads were washed five times with buffer 1 and centri-
fuged for 5 min at 1,000 g, and the supernatant was removed. The
purified MHCII or MRC1 macrophages were then shock-frozen in
liquid nitrogen and stored at 80°C until further use.
Total RNA was isolated using the RNAeasy kit from QIAGEN.
Real-time quantitative PCR (qPCR) reactions were performed in
duplicate using the MyIQ real-time PCR system (Bio-Rad). Each
25-ll reaction contained 5 ng cDNA, 12.5 ll iQ SYBR Green
Supermix (Bio-Rad), 250 nM forward and reverse primers, and
nuclease-free water. All qPCR primers were purchased from Qiagen
(QuantiTect, Qiagen). Fold changes were calculated using the
comparative CT method.
Patient characteristics
Tumors were obtained from 29 patients after informed consent and
approval of the study by the local ethical committee. Based on
central review histopathology: 11 patients were diagnosed with
primary glioblastoma multiforme (GBM) grade IV, eight patients
with relapsed GBM grade IV, three patients with primary anaplastic
oligodendroglioma grade III, one patient with primary anaplastic
astrocytoma grade III, five patients with primary oligodendroglioma
grade II and one patient with primary diffuse astrocytoma grade II.
Patient characteristics are summarized in Table EV1.
In vivo combination of anti-CSF1 mAb treatment and
temozolomide chemotherapy
Mice were intracranially injected with GL261 tumor cells as previ-
ously described (Maes et al, 2009). Briefly, 0.5 × 106 tumor cells
were injected at 2 mm lateral and 2 mm posterior from the bregma
at a depth of 3 mm below the dura mater by using a stereotactic
frame (Kopf Instruments). Stereotactic inoculation was performed
under sterile conditions.
Temozolomide (Temodal 20-mg capsules, Schering-Plough) was
delivered to the mice by gavage. In order to improve the solubility
of TMZ, an equal dose of L-histidine (Calbiochem/Merck) was
added. For each capsule that contained 20 mg TMZ, 20 mg histi-
dine was added and dissolved in a phosphate buffer. To prepare
the buffer, 2.72 g of potassium dihydrogen phosphate was added
in 1,000 ml sterile water and pH 5 was achieved by adding 1N
potassium hydroxide. The TMZ–histidine–phosphate buffer
mixture was then sonicated for 1 h, and the tube was shaken
every 20 min to avoid deposit (Branson Ultrasonics). Mice
received a dose of 40 mg/kg in 0.2 ml at days 7, 11, and 15 after
tumor inoculation.
As a control of temozolomide side effect on immune cell popula-
tion, the same administration was performed on 12-week-old
C57BL/6J mice separated into four groups: untreated without
glioma implantation (n = 3); untreated with glioma implantation
(n = 3); treated without glioma implantation (n = 3); and treated
with glioma implantation (n = 3). Three days after the last adminis-
tration, mice were sacrificed and femur and tibia were isolated.
From these bones, bone marrow was flushed using PBS followed by
erythrocyte lysis. Cells were stained for zombie near infrared (Biole-
gend) as a viability dye followed by surface staining for T-cell
population markers and general myeloid markers using the follow-
ing monoclonal antibodies: PerCP-Cy5.5-conjugated anti-CD4
(eBioscience), BV605-conjugated anti-CD11b (Biolegend), and
APC-conjugated anti-CD11c (eBioscience). Flow cytometry was
performed using a LSR Fortessa Analyzer (BD Biosciences, Erem-
bodegem, Belgium) and analyzed using FlowJo software (Tree Star,
Ashland, OR, USA).
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Anti-CSF1 mAb was diluted in saline (NaCl 0.9%, Braun) and
intraperitoneal administered at a dose of 0.5 mg at days 4, 8, 12,
and 16 after tumor inoculation.
The endpoint of the experiment was defined as three times the
median survival of the control group.
Melanoma inoculation procedure
Male mice at 10–12 weeks of age (C57Bl/6J) were used. Anti-CSF1
mAb treatment was started 2 days after subcutaneous injection of
5 × 106 B16F10 cells. Three doses of 0.5 mg of anti-CSF1 mAb
(BioXCell) were given by intraperitoneal (i.p.) injection at days 2, 6,
and 10. Tumor size was measured after the animal was sacrificed.
Statistical analysis and quantification
For continuous variables, data are presented as mean  SD or medi-
ans (interquartiles) as appropriate.
Between-group comparisons used the Mann–Whitney U-test or
t-test depending on the sample size for continuous variables.
In cases when more than two groups were compared, one-way
ANOVA test was performed, followed by Turkey’s multiple compar-
ison test, and results were considered significantly different if
P < 0.05.
For correlation analysis, Spearman’s correlation test was
performed.
For survival experiment, log-rank (Mantel–Cox) tests and
multiple comparison test were performed.
A two-tailed value of P < 0.05 was considered statistically significant.
All the analyses were performed using Prism 6.0 software
(GraphPad).
For mice in vivo imaging quantification, three fields per animal
were pictured in the tumor center and blood vessel caliber, branch-
ing, vessel perfusion, and distance of macrophages to blood vessel
were analyzed using Fiji software.
For mice ex vivo and human sample imaging quantification,
five fields per individual were pictured in the tumor center (or
tumor periphery when mentioned) and vessel caliber, vessel
branching, number of macrophages and resident macrophages,
overlapping stainings, macrophages proliferation, hypoxic area,
and tumor double-strand DNA damages were quantified using Fiji
software.
Expanded View for this article is available online.
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